Ankylosing Spondylitis

 

Filip Van den Bosch, MD: Safety and Efficacy of Upadacitinib for nr-axSpA

June 03, 2022

Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."

Upadacitinib Achieves Promising Results for Axial Spondyloarthritis Treatment

June 03, 2022

Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.

Q&A: IL-18 Serum Levels and Cardiovascular Risk in Psoriatic Arthritis, Ankylosing Spondylitis

March 07, 2022

In this Q&A, Krzysztof Bonek, MD, PhD, discussed the findings of his study that looked at the associations of IL-18 serum levels with serum lipids, cardiovascular risk and disease activity in patients with ankylosing spondylitis and psoriatic arthritis.

Fatigue and Pain Levels Remain High in Patients With Ankylosing Spondylitis

December 02, 2021

“Managing pain is an important treatment goal in patients with ankylosing spondylitis, however, pain is often underestimated by clinical disease activity scoring tools, and 20% to 30% of patients report pain despite treatment with TNFis,” investigators stated.